Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

M A Stone, U Payne, C Pacheco-Tena, R D Inman

Research output: Contribution to journalArticle

37 Citations (Scopus)


Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p
Original languageEnglish
Pages (from-to)84-87
Number of pages4
JournalAnnals of the Rheumatic Diseases
Issue number1
Publication statusPublished - 2004


Cite this